Literature DB >> 35078347

Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018).

Elisa Pasqual1, Julie Ann Sosa2, Yingxi Chen1, Sara J Schonfeld1, Amy Berrington de González1, Cari M Kitahara1.   

Abstract

Background: In response to evidence of overdiagnosis and overtreatment of papillary thyroid carcinoma (PTC), the 2009 and 2015 American Thyroid Association (ATA) adult guidelines recommended less extensive surgery (lobectomy vs. total thyroidectomy) and more restricted use of postsurgical radioactive iodine (RAI) in management of PTC at low risk of recurrence. In 2015, active surveillance was suggested as a viable option for some <1-cm PTCs, or microcarcinomas. The 2015 ATA pediatric guidelines similarly shifted toward more restricted use of RAI for low-risk PTCs. The impact of these recommendations on low-risk adult and pediatric PTC management remains unclear, particularly after 2015.
Methods: Using data from 18 Surveillance, Epidemiology, and End Results (SEER) U.S. registries (2000-2018), we described time trends in reported first-course treatment (total thyroidectomy alone, total thyroidectomy+RAI, lobectomy, no surgery, and other/unknown) for 105,483 patients diagnosed with first primary localized PTC (without nodal/distant metastases), overall and by demographic and tumor characteristics.
Results: The declining use of RAI represented the most pronounced change in management of PTCs <4 cm (44-18% during the period 2006-2018), including microcarcinomas (26-6% during the period 2007-2018). In parallel, an increasing proportion of PTCs were managed with total thyroidectomy alone (35-54% during the period 2000-2018), while more subtle changes were observed for lobectomy (declining from 23% to 17% during the period 2000-2006, stabilizing, and then rising from 17% to 24% during the period 2015-2018). Use of nonsurgical management did not meaningfully change over time, impacting <1% of microcarcinomas annually during the period 2000-2018. Similar treatment trends were observed by sex, age, race/ethnicity, metropolitan vs. nonmetropolitan residence, and insurance status. For pediatric patients (<20 years), use of RAI peaked in 2009 (59%), then decreased markedly to 11% (2018), while use of total thyroidectomy alone and, to a lesser extent, lobectomy increased. No changing treatment trends were observed for ≥4-cm PTCs. Conclusions: The declining use of RAI in management of low-risk adult and pediatric PTC is consistent with changing recommendations from the ATA practice guidelines. Post-2015 trends in use of lobectomy and nonsurgical management of low-risk PTCs, particularly microcarcinomas, were more subtle than expected; however, these trends may change as evidence regarding their safety continues to emerge.

Entities:  

Keywords:  clinical guidelines; papillary thyroid carcinoma; treatment trends

Mesh:

Substances:

Year:  2022        PMID: 35078347      PMCID: PMC9048184          DOI: 10.1089/thy.2021.0557

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.506


  46 in total

Review 1.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

Review 2.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?

Authors:  Bryan R Haugen
Journal:  Cancer       Date:  2016-10-14       Impact factor: 6.860

4.  Current thyroid cancer trends in the United States.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

5.  Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes.

Authors:  Iwao Sugitani; Kazuhisa Toda; Keiko Yamada; Noriko Yamamoto; Motoko Ikenaga; Yoshihide Fujimoto
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

6.  Patient Preferences Around Extent of Surgery in Low-Risk Thyroid Cancer: A Discrete Choice Experiment.

Authors:  Sara Ahmadi; Juan Marcos Gonzalez; Maya Talbott; Shelby D Reed; Jui-Chen Yang; Randall P Scheri; Michael Stang; Sanziana Roman; Julie Ann Sosa
Journal:  Thyroid       Date:  2020-04-15       Impact factor: 6.568

Review 7.  Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.

Authors:  Lisa M Lowenstein; Spyridon P Basourakos; Michelle D Williams; Patricia Troncoso; Justin R Gregg; Timothy C Thompson; Jeri Kim
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

Review 8.  Progress and Challenges in Thyroid Cancer Management.

Authors:  Megan R Haymart
Journal:  Endocr Pract       Date:  2021-09-22       Impact factor: 3.443

9.  Comparison of SEER Treatment Data With Medicare Claims.

Authors:  Anne-Michelle Noone; Jennifer L Lund; Angela Mariotto; Kathleen Cronin; Timothy McNeel; Dennis Deapen; Joan L Warren
Journal:  Med Care       Date:  2016-09       Impact factor: 3.178

10.  Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.

Authors:  Lauren P Wallner; Mousumi Banerjee; David Reyes-Gastelum; Ann S Hamilton; Kevin C Ward; Carrie Lubitz; Sarah T Hawley; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

View more
  4 in total

1.  Opportunities and Challenges of Defining "Value" in Oncology Care.

Authors:  Nicole M Mott; Lesly A Dossett
Journal:  Ann Surg Oncol       Date:  2022-03-22       Impact factor: 4.339

2.  Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?

Authors:  Ian D Hay; Suneetha Kaggal; Geoffrey B Thompson
Journal:  Eur Thyroid J       Date:  2022-07-12

3.  Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.

Authors:  Hengqiang Zhao; Yiping Gong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

4.  Retrospective analysis of clinical characteristics and risk factors of differentiated thyroid cancer in children.

Authors:  Chun Chen; Lei Hang; Yan Wu; Qing Zhang; Yifei Zhang; Jun Yang; Jin Xie; Jingrong Lu
Journal:  Front Pediatr       Date:  2022-09-12       Impact factor: 3.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.